On December 7, 2017, Denali Therapeutics, a biotech company that develops new molecular therapies for neurodegenerative diseases, announced its initial public offering of 13,888,888 million shares of its Class A common stock at a price to the public of $18 per share, resulting in estimated net proceeds to the company of $250,000,000. The shares began trading on the Nasdaq exchange on December 8, 2017, under the ticker symbol "DNLI." Wilson Sonsini Goodrich & Rosati represented Denali in the offering.

Goldman Sachs & Co. LLC, Morgan Stanley, and J.P. Morgan are acting as joint book-running managers for the offering, and Evercore Group L.L.C. is acting as lead manager for the offering.

The Wilson Sonsini team that represented Denali in the offering included partner Tony Jeffries, partner-elect Jennifer Knapp, and associate Cathy Doxsee.

For more information, please see Denali's press release.